For the year ending 2025-12-31, BLFS had -$62,348K decrease in cash & cash equivalents over the period. $10,637K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -4,595 |
| Impairment of intangible assets | 0 |
| Impairment of long-lived assets | 0 |
| Gain on settlement of global cooling escrow | 0 |
| Depreciation | 2,253 |
| Amortization of intangible assets | 2,434 |
| Amortization of loan costs | 0 |
| Stock-based compensation | 22,993 |
| Non-cash lease expense | 1,875 |
| Deferred income tax expense (benefit) | 65 |
| Change in fair value of contingent consideration | 0 |
| Change in fair value of equity investment and other | 983 |
| Accretion of investments | 736 |
| Loss on disposal of assets held for rent, net | -510 |
| Loss on disposal of property and equipment, net | -11 |
| Ipr&d expense | 15,521 |
| Net gain on disposal of subsidiaries | 10,324 |
| Accounts receivable, trade, net | -264 |
| Inventories | 1,268 |
| Prepaid expenses and other current assets | 3,039 |
| Accounts payable | -2,086 |
| Accrued expenses and other current liabilities | -1,144 |
| Sales taxes payable | -1,905 |
| Warranty liability | 5 |
| Other | 264 |
| Net cash provided by (used in) operating activities | 20,115 |
| Purchases of property and equipment | 9,478 |
| Purchases of assets held for rent | 886 |
| Proceeds from sale of available-for-sale securities | 6,829 |
| Maturities of available-for-sale securities | 34,764 |
| Investment in available-for-sale securities | 114,063 |
| Purchases of intangible assets | 0 |
| Investment in ipr&d | 10,221 |
| Investment in convertible promissory note | 2,000 |
| Proceeds from sale of divested entities | 23,516 |
| Payments on divestiture of global cooling | 0 |
| Net cash (used in) provided by investing activities | -71,539 |
| Payments on term loan | 10,000 |
| Payments on equipment loans | 0 |
| Issuance of common stock | 0 |
| Proceeds from exercise of common stock options | 18 |
| Proceeds from financed insurance premium | 0 |
| Payments on financed insurance premium | 975 |
| Other | 33 |
| Net cash (used in) provided by financing activities | -10,924 |
| Net (decrease) increase in cash and cash equivalents | -62,348 |
| Cash and cash equivalents beginning of period | 95,386 |
| Effects of currency translation on cash and cash equivalents | 0 |
| Cash and cash equivalents end of period | 33,038 |
BIOLIFE SOLUTIONS INC (BLFS)
BIOLIFE SOLUTIONS INC (BLFS)